Granite Bio secures $100m in funding for new antibodies
The financial injection comprises a $30m Series A round and a $70m Series B round.
Drug Development
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
Pharma companies in Europe push for US-level drug prices
Repertoire and Genentech to develop autoimmune disease therapies
Biogen’s Friedreich’s ataxia treatment authorised in UK
EditCo Bio secures access to Promega’s technologies in licensing deal
ConcertAI and Bayer to boost precision oncology with AI and ML insights
TNF and Renova Health use AI to identify patients for GLP-1 treatments
